Clinical trials: sponsored by Jemincare
ADPKD (Autosomal Dominant Polycystic Kidney Disease), Renal Edema
A Study to Investigate the Pharmacokinetics of JMKX003142 in Healthy Participants and Participants With Hepatic Impairment
The primary purpose of this study is to evaluate the plasma PK of JMKX003142 following a single dose in participants with mild and moderate hepatic impairment compared to matched healthy participants with normal hepatic function.
- Trial name
- NCT07909070
- Testing
- JMKX003142
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Jemincare
Pain After Surgery
Phase I Study of JY1001 Injection
The goal of this dose esclation study is to evaluate the safety, tolerability, and PK characteristicsafter of a single dose of JY1001 injection in healthy participants. A total of 6 cohorts are planned to be evaluated.
- Trial name
- NCT07848945
- Testing
- JY1001
- Where
- China
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Jemincare
ADPKD (Autosomal Dominant Polycystic Kidney Disease)
Drug-Drug Interactions of JMKX003142 in Healthy Participants
This is a single-center, non-randomized, open-label, self-controlled, Phase I clinical trial to evaluate the drug-drug interactions (DDI) of JMKX003142 tablets in healthy adult participants.
- Trial name
- NCT07565441
- Testing
- JMKX003142 tablets, Fluconazole Capsules, Cocktail Substrates (Midazolam Oral Solution, Rosuvastatin Calcium Tablets, and Digoxin Tablets)
- Volunteers
- 112 people, healthy volunteers welcome
- Sponsor
- Jemincare
ADPKD (Autosomal Dominant Polycystic Kidney Disease)
A Study to Investigate the Effects of JMKX003142 on QTc Interval in Healthy Adults
The primary objective of this study is to assess the effect of a therapeutic and supratherapeutic oral dose of JMKX003142 on the corrected cardiac QT interval relative to a placebo in healthy participants
- Trial name
- NCT07470177
- Testing
- JMKX003142 tablets
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Jemincare
ADPKD (Autosomal Dominant Polycystic Kidney Disease)
Mass Balance and Absolute Bioavailability Study of JMKX003142 In Healthy Volunteers
A phase 1 healthy volunteer study to assess the excretion and metabolism as well as the absolute bioavailability of oral JMKX003142.
- Trial name
- NCT07463053
- Testing
- [14C]JMKX003142, JMKX003142 tablets, [14C]JMKX003142 solution for infusion
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Jemincare
Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Drug-Drug Interaction of JMKX003142 With Amiodarone and Febuxostat in Healthy Subjects
This is a open-label, non-randomized, multiple oral dosings, three-period, drug-drug interaction study of JMKX003142 tablet, Amiodarone Hydrochloride Tablets and Febuxostat Tablets in Chinese healthy adult subjects
- Trial name
- NCT07181265
- Testing
- Amiodarone Hydrochloride Tablets, Febuxostat Tablets
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Jemincare
Age-Related Macular Degeneration (AMD), Diabetic Macular Edema (DME)
Study of JMKX003948 Ophthalmic Suspension in Healthy Participants
The study is a randomized, double-blind, placebo-controlled, phase 1 study of JMKX003948 Ophthalmic Suspension to evaluate the safety, tolerability and PK of single and multiple ascending doses in healthy participants.
- Trial name
- NCT06832657
- Testing
- JMKX003948 Ophthalmic Suspension
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Jemincare
ADPKD (autosomal Dominant Polycystic Kidney Disease)
Study to Evaluate the Drug-drug Interaction of JMKX003142 in Healthy Subjects
To evaluate the effects of oral administration rifampicin or itraconazole capsules on the pharmacokinetics of JMKX003142 in healthy subjects.
- Trial name
- NCT06658964
- Testing
- Cohort 1: JMKX003142 and itraconazole, Cohort 2: JMKX003142 and rifampicin
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Jemincare
Healthy
Trial of JMKX003801 in Healthy Participants
To Evaluate the Safety, Tolerability, and Pharmacokinetic Characteristics of JMKX003801 Administered Randomly, Double-blind, Placebo-controlled, Single-ascending Dose and Multiple-ascending Dose in Chinese Healthy Adult…
- Trial name
- NCT06549309
- Testing
- JMKX003801
- Where
- China
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Jemincare
Solid Tumor, Adult
To Assess the Effects of Single Dose of JMKX001899 on QTc Interval in Healthy Subjects
Study to assess the effect of JMKX001899 on QTc interval in healthy volunteers
- Trial name
- NCT06473948
- Testing
- JMKX001899
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Jemincare
Solid Tumor, Adult
Study to Evaluate the Drug-drug Interaction of JMKX001899 in Healthy Subjects
This is an open-label, non-randomized, clinical study to evaluate the drug interaction between itraconazole, rifampin or Cocktail and JMKX001899 in healthy subjects.
- Trial name
- NCT06348290
- Testing
- JMKX001899, Itraconazole, Midazolam
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Jemincare
Healthy Adult
Study of JMKX003142 Injection in Chinese Healthy Subjects
To Evaluate the Safety, Tolerability, and Pharmacokinetic Characteristics of JMKX003142 Injection Administered Randomly, Double-blind, Placebo-controlled, Single-ascending Dose and Multiple-ascending Doses in Chinese Healthy…
- Trial name
- NCT06344533
- Testing
- JMKX003142 Injection
- Where
- China
- Volunteers
- 78 people, healthy volunteers welcome
- Sponsor
- Jemincare
Safety and Tolerability
Phase 1 Clinical Study of JMKX003142 Tablets
Phase I clinical study to evaluate the safety, tolerability, and pharmacokinetic characteristics of JMKX003142 tablets administered randomly, double-blind, placebo-controlled single and multiple times in healthy adult subjects…
- Trial name
- NCT06079541
- Testing
- JMKX003142 will be administered orally
- Where
- China
- Volunteers
- 106 people, healthy volunteers welcome
- Sponsor
- Jemincare
Healthy
Study of JYB1904 (an Anti-immunoglobulin E Antibody) in Healthy Chinese Subjects
This phase Ia study is meant to evaluate the tolerability, safety, pharmacokinetics, preliminary pharmacodynamics, and immunogenicity of single-dose JYB1904, an anti-immunoglobulin E (IgE) antibody, in healthy Chinese subjects.
- Trial name
- NCT05449535
- Testing
- JYB1904, Omalizumab
- Where
- China
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Jemincare
Safety and Tolerability
Safety, Tolerability of JMKX003002 in Phase 1 Study in Healthy Subjects
Safety, tolerability, pharmacokinetics, and pharmacodynamics of JMKX003002 in single and multiple ascending dose randomized，doubled-blind phase 1 study in healthy subjects
- Trial name
- NCT05907382
- Testing
- JMKX003002 will be administered orally
- Where
- China
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Jemincare